Scientific Program 07.01.20 - 11.01.20, ,

The 20th Annual Meeting of the Israeli Society of Clinical Oncology and Radiotherapy הוועדה המארגנת ISCORT wishes to express its gratitude to the following companies Organizing Committee ISCORT 20 for their support of the 20th ISCORT Annual Meeting: נשיא הכנס: :President פרופ׳ ברוך ברנר Platinum Sponsor Baruch Brenner, MD מזכיר האונקולוגיה הרפואית: :Roche Secretary, Medical Oncology ד״ר נעם אסנה Gold Sponsor Noam Asna, MD מזכירת הרדיותרפיה: :AstraZeneca Secretary, Radiation Oncology ד״ר סבטלנה זלמנובה MSD Svetlana Zalmanova, MD Novartis הוועדה המדעית Scientific Committee ISCORT 20 Pfizer יו״ר: פרופ׳ אהרון סולקס Silver Sponsor Chairman: Aaron Sulkes, MD סגן יו״ר: פרופ׳ גל מרקל Assuta Deputy Chairman: Gal Markel, MD, PhD מזכיר: ד״ר אסף מור Astellas Secretary: Assaf Moore, MD ד״ר יאיר בר BMS Jair Bar, MD, PhD פרופ׳ גיל בר-סלע Eli Lilly Gil Bar-Sela, MD פרופ׳ אלברטו גביזון Alberto Gabizon, MD, PhD Medison פרופ׳ עידו וולף Ido Wolf, MD ד״ר מרק ויגודה Oncotest Rhenium Marc Wygoda, MD ד״ר אמיר זוננבליק Rafa Amir Sonnenblick, MD פרופ׳ ג‹אמל זידאן Sanofi Jamal Zidan, MD ד״ר אלונה זר Teva Alona Zer, MD פרופ׳ רינת ירושלמי Varian Rinat Yerushalmi, MD ד״ר דרור לימון Dror Limon, MD ד״ר מור מושקוביץ Bronze Sponsor Mor Moskovitz, MD ד״ר בלאן סאלם AAA Salem Billan, MD פרופ׳ טלי סיגל Ami Technologies Tali Siegal, MD פרופ׳ תמר ספרא Bayer Tamar Safra, MD פרופ׳ ביאטריס עוזיאלי Boehringer Ingelheim Beatrice Uziely, MD פרופ׳ אהרון פופובצר Desit Aron Popovtzer, MD פרופ׳ רפאל קטן Raphael Catane, MD ד״ר דניאל קייזמן Dexcel Pharma Daniel Keizman, MD ד״ר אלי רוזנבאום ISI Eli Rosenbaum, MD ד״ר אורה רוזנגרטן Janssen Ora Rosengarten, MD ד״ר קטרינה שולמן Merck Katerina Shulman, MD ד״ר עינת שחם-שמואלי Nanostring Einat Shacham-Shmueli, MD Neopharm החברה המארגנת Organizing Company Perrigo א.מ. כנסים בע"מ .Takeda I.M. Knasim Ltd

חברים נכבדים, ,Dear friends and colleagues אנו מתכבדים להזמינכם להשתתף בכינוס של האיגוד הישראלי לאונקולוגיה We are honored to cordially invite you to participate in the 20th Annual Meeting קלינית ורדיותרפיה, ISCORT 20, אשר יתקיים באילת בין 7-11 לינואר of the Israel Society of Clinical Oncology and Radiotherapy (ISCORT), which will .2020 הנושא המרכזי בכינוס הוא ״עמיתים מעדכנים עמיתים״, שנבחר לאור ייחודו של s central theme will be׳be held in Eilat between January 7-11, 2020. The meeting which was selected as a result of the meeting’s ,״Colleagues Update Colleagues״ כנס ISCORT מכנסים אחרים; אין זה כנס המתמקד בתחום אחד באונקולוגיה ואין unique nature, which does not focus on a single issue nor is it devoted mainly זה כנס בו מאזינים מקומיים רבים מתקבצים כדי לשמוע מוביל דעה עולמי. כנס to learn from international opinion leaders. ISCORT is, in its essence, a meeting ISCORT במהותו הוא מפגש נעים ומפרה של עמיתים ישראליים, בו אונקולוגים of Israeli colleagues in which oncologists specializing in one field update their מתחום אחד מתעדכנים מעמיתיהם על ההתקדמויות האחרונות בתחום בו הם colleagues on the latest developments in their area of interest. The choice to emphasize this nature of ISCORT Meeting derived not only from a wish but rather מתמקצעים. הבחירה להבליט אופיו זה של כנס ISCORT נבעה לא רק מהרצון, from the ability; we have witnessed substantial progress in the Oncology specialty אלא גם מהיכולת; בשנים האחרונות התפתח מאד מקצוע האונקולוגיה בארץ, in Israel in recent years, with the formation of a cadre of many specialists in תוך התהוות שכבה של אנשי מקצוע רבים הניצבים בחזית העשייה בתחום the forefront of professional activity, who are also very capable of sharing their או תת-תחום בו הם עוסקים, ואשר בורכו ביכולת להעביר את הידע והניסיון knowledge and expertise with their colleagues. ISCORT serves therefore, as an הרב שצברו לעמיתיהם. במצב זה, רק מתבקש שכנס ISCORT יהווה את הבמה optimal platform for information exchange between Israeli colleagues. With this המיטבית לחילופי מידע בין עמיתים ישראליים. ברוח זו, שפת הכנס תהיה ככלל -spirit, the Meeting will be conducted in Hebrew, except for sessions with a non בעברית, להוציא ישיבות בהן יהיה מרצה אורח. .Israeli speaker In parallel with enriching the knowledge in main oncology fields, particularly those לצד העשרת הידע בתחומים המרכזיים באונקולוגיה, ובייחוד באלה בהם חלה in which substantial progress has taken place over the past year since the last התקדמות משמעותית בשנה שחלפה מכנס ISCORT הקודם, נבחרו השנה גם ISCORT meeting, we have chosen this year to update several cross cutting topics מספר נושאים חוצי-תחומים עדכניים, המסקרנים ומטרידים בו זמנית את מרבית which intrigue and concern most oncologists both in Israel and worldwide. Among האונקולוגים בארץ ובעולם. בין אלה נכללו המחירים האפשריים של בדיקות ,these, we have included sessions about the potential costs of cancer screening סקר, הביולוגיה והאימונולוגיה של מחלת הסרטן, והמחלה האוליגו-גרורתית. .cancer biology and immunology and oligometastatic disease Like prior organizing committees, we have also invested a major effort in creating בדומה לוועדות מארגנות קודמות, גם אנו השקענו מאמץ רב כדי לבנות תכנית an interesting and varied program. The meeting includes lectures, reviews מדעית מעניינת ומגוונת. הכינוס מורכב מהרצאות, סקירות של פרסומים of leading publications, multidisciplinary case presentations and discussions מובילים, דיוני מקרים רב-תחומיים, ודיונים בנושאים הנתונים במחלוקת. כמו on controversial issues. In addition, outstanding works will be presented by כן, יוצגו עבודות מצטיינות ממרכזים שונים בארץ, מתחומי מחקר קליני, תרגומי oncologists from various Israeli institutions on clinical, translational and basic ובסיסי. .science topics Notwithstanding the emphasis on the input of Israeli oncologists, we will also למרות הדגש על מרצים ישראליים, עדיין יכבדו אותנו בהשתתפותם גם אורחים be honored to welcome guests from abroad who will undoubtedly enrich our מחו״ל, אשר ללא ספק יעשירו את הבנתנו בנושאים מסוימים באונקולוגיה. understanding of specific topics in Oncology. We would like to express our special בהזדמנות זו נרצה להודות באופן מיוחד לוועדה המדעית בראשותם של פרופ׳ thanks to the Scientific Committee lead by Prof. Aaron Sulkes (chairman), Prof. Gal אהרון סולקס )יו״ר הועדה(, פרופ׳ גל מרקל )סגן יו״ר( וד״ר אסף מור )מזכיר(, על Markel (vice-chairman) and Dr. Assaf Moore (secretary) for their thorough work עבודה יסודית ביותר בבחירת התקצירים אשר יוצגו בכינוס. .and commitment in selecting the best abstracts to be presented at the meeting מצפים לכם באילת ומאחלים לכולם עניין והנאה כאחד. We look forward to meeting you in Eilat and wish you a pleasant and fruitful meeting. בברכה, ,Sincerely פרופ׳ ברוך ברנר ד״ר נעם אסנה ד״ר סבטלנה זלמנובה Prof. Baruch Brenner Dr. Noam Asna Dr. Svetlana Zalmanova נשיא הכינוס מזכיר האונקולוגיה מזכירת הרדיותרפיה (President Secretary (Medical Secretary (Radiotherapy Oncology) Oncology) Keynote Lecture Tuesday, January 7, 2020 Moderator: Miri Ziv Vice Chairman, Israel Cancer Association, 17.00-18.50 Opening Session Givatayim, Israel Moderator: Noam Asna, MD , , Israel 18.20-18.50 Cancer Screening: Benefits only? Otis Webb Brawley, MD 17.00-17.20 Welcome Johns Hopkins University, Baltimore, USA Baruch Brenner, MD Davidoff Center, , Petach 19.30 Dinner Tikva, Israel Wilmosh Mermershtain, MD Chairman, ISCORT 17.20-17.30 Resident Recognition Award Avraham Kuten, MD Chair, Israel Cancer Association, Givatayim, Israel 17.30-18.20 Best ISCORT Abstracts and Publications Awards Moderator: Aaron Sulkes, MD Davidoff Center, Rabin Medical Center, Petach Tikva, Israel Radiation Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer Merav A. Ben David, MD , Tel-Aviv, Israel Adaptation of Colon Cancer Cells to the Brain Microenvironment: The Role of IRS2 Ido Wolf, MD Sourasky Medical Center, Tel-Aviv, Israel Incidence and Risk Factors of Arterial Thromboembolism (ATE) and Venous Thromboembolism (VTE) in Non-Small Cell Lung Cancer (NSCLC) Alona Zer, MD Davidoff Center, Rabin Medical Center, Petach Tikva, Israel Best Publications 2019 09.50-10.30 Tumor Board - Esophageal Cancer Wednesday, January 8, 2020 Moderator: Sharon Pelles, MD Sourasky Medical Center, Tel-Aviv, Israel 07.30-08.10 Meet the Professor - SBRT Tarshish A Hall Panel: Alon Ben-Nun, MD, PhD , Ramat-Gan, Israel Raphael Pfeffer, MD Assuta Medical Center, Tel-Aviv, Israel Marc Wygoda, MD Supported by Assuta Medical Centers , , Israel Gastro-Intestinal Malignancies - Part I Nirit Yarom, MD Shamir (Asaf Harofe) Medical Center, , Moderators: Ofer Purim, MD Israel Assuta Medical Center, , Israel 10.30-10.45 Coffee Break Yaacov Lawrence, MD Sheba Medical Center, Ramat-Gan, Israel Gastro-Intestinal Malignancies - Part II 08.20-08.40 Current Treatment of Advanced Pancreatic Moderators: Sofia Man, MD Cancer , Beer Sheva, Israel Talia Golan, MD Eyal Fenig, MD Sheba Medical Center, Ramat-Gan, Israel Davidoff Center, Rabin Medical Center, Petach Supported by AstraZeneca and MSD Tikva, Israel 08.40-09.00 Radiotherapy in Colorectal Cancer 10.45-11.05 Current Treatment of Advanced HCC Ross Abrams, MD Ravit Geva, MD Hadassah Medical Center, Jerusalem, Israel Sourasky Medical Center, Tel-Aviv, Israel 09.00-09.20 Current Treatment of Metastatic Esophago- Supported by Roche Gastric Cancers 11.05-11.20 Best of GI 2019 Ayala Hubert, MD Valeria Seministy, MD Hadassah Medical Center, Jerusalem, Israel Rambam Medical Center, , Israel Supported by MSD 09.20-09.50 Pro & Con: Is There a Role for Radiotherapy in Pancreatic Cancer? Moderator: Katerina Shulman, MD Hillel Yaffe Medical Center, , Israel Pro: Raphael Pfeffer, MD Assuta Medical Center, Tel-Aviv, Israel Con: Einat Shacham-Shmueli, MD Sheba Medical Center, Ramat-Gan, Israel Supported by Assuta Medical Centers 11.20-12.10 Original Abstracts – Part I: 12.10-12.40 Cancer Immunology A Critique of the Fragility Index in Oncological Antoni Ribas, MD, PhD Trials University of California Los Angeles, Los Angeles, Tomer Meirson, MD, PhD student USA Bar-Ilan University, Faculty of Medicine in the Supported by MSD Galilee 12.40-13.25 Lunch A Phase II Randomized, Double-Blind, Keynote Lecture Placebo-controlled Trial of Namodenoson as 2nd-line Therapy in Patients with Advanced Moderator: Jacob Schachter, MD Hepatocellular Carcinoma and Child-Pugh B Sheba Medical Center, Ramat-Gan, Israel Cirrhosis 13.25-13.55 Resistance to Immunotherapy Solomon Stemmer, MD Antoni Ribas, MD, PhD Davidoff Center, Rabin Medical Center, Petach University of California Los Angeles, Los Angeles, Tikva, Israel USA Pharmacokinetics of Mitomycin-c Lipidic Prodrug Supported by MSD Entrapped in Liposomes (Promitil) and Clinical Genito-Urinary Malignancies - Part I Correlations in Metastatic Colorectal Cancer Moderators: Daniel Goldstein, MD Patients Davidoff Center, Rabin Medical Center, Petach Alberto Gabizon, MD, PhD Tikva, Israel Shaare Zedek Medical Center, Jerusalem, Israel Eliahu Gez, MD When Do Colorectal Tumors Die Following Ziv Medical Center, , Israel Therapy? Albert Grinshpun, MD 13.55-14.15 Systemic Therapy in High Risk Prostate Cancer Hadassah Medical Center, Jerusalem, Israel Eli Rosenbaum, MD Davidoff Center, Rabin Medical Center, Petach Next Generation Sequencing in Salivary Gland Tikva, Israel Carcinoma - Do Targetable Alterations Lead Supported by Teva to a Therapeutic Advantage? A Multicenter Experience 14.15-14.35 Radiotherapy in High Risk Prostate Cancer Assaf Moore, MD Tomer Charas, MD Davidoff Center, Rabin Medical Center, Petach Rambam Medical Center, Haifa, Israel Tikva, Israel Supported by Electa 14.35-14.55 Upfront Management of Metastatic RCC: IO- Keynote Lecture VEGFi or IO-IO Moderator: Jacob Schachter, MD Victoria Neiman, MD Sheba Medical Center, Ramat-Gan, Israel Davidoff Center, Rabin Medical Center, Petach Tikva, Israel Supported by BMS and MSD 14.55-15.25 Pro & Con: Organ Preservation in Bladder Cancer 16.40 -16.55 Best of GU 2019 Moderator: David Sarid, MD Keren Rouvinov, MD Sourasky Medical Center, Tel-Aviv, Israel Soroka Medical Center, Beer Sheva, Israel Supported by Astellas Pro: Mark Wygoda, MD Hadassah Medical Center, Jerusalem, Israel 16.55-17.45 Original Abstracts – Part II: Con: Ofer Yosepovich, MD The Role of Myc in Interferon-γ Signaling Sourasky Medical Center, Tel-Aviv, Israel Inhibition and Immunotherapy Resistance in Advanced Melanoma Patients 15.25-15.45 Metastatic Bladder Cancer Ettai Markovits, MD Avivit Peer, MD Sheba Medical Center, , Israel Rambam Medical Center, Haifa, Israel Supported by MSD Real-World Analysis of Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) Patients 15.45-16.00 Coffee Break in Israel: Outcomes and Associated Factors Genito-Urinary Malignancies - Part II Keren Rouvinov, MD Moderators: Wilmosh Mermershtain, MD Soroka Medical Center, Beer Sheva, Israel Chairman, ISCORT The Association between Allopurinol Use and Zvi Symon, MD Urologic Malignancies: A Nested Case-Control Sheba Medical Center, Ramat-Gan, Israel Study Daniel Keizman, MD 16.00-16.40 Tumor Board- Prostate Cancer Sourasky Medical Center, Tel-Aviv, Israel Moderator: Raanan Berger, MD, PhD Radiosurgery Compared To External Beam Sheba Medical Center, Ramat-Gan, Israel Radiotherapy for Localized Spine Metastasis: Panel: Tomer Charas, MD Phase III Results of NRG Oncology/RTOG 0631 Rambam Medical Center, Haifa, Israel Aaron Allen, MD Daniel Keizman, MD Davidoff Center, Rabin Medical Center, Petach Sourasky Medical Center, Tel-Aviv, Israel Tikva, Israel Avivit Peer, MD A Phase 2 Single Arm Study of Nivolumab and Rambam Medical Center, Haifa, Israel Ipilimumab (Nivo/Ipi) in Previously Treated Classical Kaposi Sarcoma (CKS) Eli Rosenbaum, MD Alona Zer, MD Davidoff Center, Rabin Medical Center, Petach Davidoff Center, Rabin Medical Center, Petach Tikva, Israel Tikva, Israel Supported by Jansen 09.50-10.30 Tumor Board - NSCLC Thursday, January 9, 2020 Moderator: Jair Bar, MD, PhD Sheba Medical Center, Ramat-Gan, Israel 07.00-08.00 ISCORT Discussion: Residency Panel: Alon Ben-Nun, MD, PhD Moderator: Wilmosh Mermershtain, MD Sheba Medical Center, Ramat-Gan, Israel Chairman, ISCORT Michael Brada, FRCP, FRCR, DSc 07.30-08.10 Meet the Professor - Melanoma Radiation Oncology, University of Liverpool, GB Tarshish A Hall Maya Gottfried, MD Peter Mohr, MD Meir Medical Center, , Israel Elbe Kliniken, Stade, Germany Dov Hershkovitz, MD Supported by Novartis Sourasky Medical Center, Tel-Aviv, Israel Lung Cancer - Part I Natasha B. Leighl, M.D Moderators: Abed Agbarya, MD Princess Margaret Hospital, Toronto, Canada , Haifa, Israel Damian Urban, MD Tatiana Rabin, MD Sheba Medical Center, Ramat-Gan, Israel Sheba Medical Center, Ramat-Gan, Israel Supported by AstraZeneca and MSD 08.20-08.40 Molecular-Based Treatment of NSCLC 10.30-10.45 Coffee Break Mor Moskovitz, MD Lung Cancer - Part II Rambam Medical Center, Haifa, Israel Supported by Roche Moderators: Ofer Merimsky, MD Sourasky Medical Center, Tel-Aviv, Israel 08.40-09.00 Non-Surgical Treatment in Stage III NSCLC Michael Brada, FRCP, FRCR, DSc Amichai Meirovich, MD Radiation Oncology, University of Liverpool, GB Hadassah Medical Center, Jerusalem, Israel 09.00-09.20 Sequential Treatment Lines in NSCLC 10.45-11.05 Neuroendocrine Carcinomas and SCLC Nir Peled, MD, PhD Alona Zer, MD Soroka Medical Center, Beer Sheva, Israel Davidoff Center, Rabin Medical Center, Petach Tikva, Israel 09.20-09.50 Pro & Con: Is Surgery Mandatory in Stage I Lung Supported by Roche Cancer? 11.05-11.25 Immunotherapy in Lung Cancer: Future Moderator: Maya Gottfried, MD Perspectives Meir Medical Center, Kfar Saba, Israel Natalie Maimon-Rabinovich, MD Pro: Aaron Allen, MD Meir Medical Center, Kfar Saba, Israel Davidoff Center, Rabin Medical Center, Petach Supported by MSD Tikva, Israel 11.25-11.40 Best of Lung 2019 Con: Alon Ben-Nun, MD, PhD Sivan Shamay, MD Sheba Medical Center, Ramat-Gan, Israel Sourasky Medical Center, Tel-Aviv, Israel Supported by AstraZeneca 11.40-12.30 Original Abstracts – Part III: 13.15-13.45 Cancer Development Venous Thromboembolism in Patients with Heinz-Josef Lenz, MD Advanced Non-Small Cell Lung Cancer Treated USC Norris Comprehensive Cancer Center, Los with Immune Check-Point Inhibitors – A Angeles, USA Retrospective Cohort Study Oligometastatic Disease – Special Session Oded Icht, MD Moderators: Neil Friedman, MD Davidoff Center, Rabin Medical Center, Petach , , Israel Tikva, Israel Salem Billan, MD Comparative Effectiveness of Intensity Rambam Medical Center, Haifa, Israel Modulated Radiation Therapy to 3-Dimensional Conformal Radiation in Locally Advanced Lung 13.45-14.05 The Biology of Oligometastatic Disease Cancer: Pathological and Clinical Outcomes Yuval Shaked, PhD Sarit Appel, MD Technion Faculty of Medicine, Haifa, Israel Sheba Medical Center, Ramat Gan, Israel 14.05-14.25 Radiotherapy for Oligometastatic Disease The Impact of an Oncologist-Supervised Cancer Benjamin Movsas, MD Diagnostic Clinic on Time-to-Treatment (TTT) in Radiation Oncology, Henry Ford Hospital, Detroit, Advanced Lung Cancer USA Opher Globus, MD Supported by VaRay Sheba Medical Center, Ramat Gan, Israel 14.25-14.45 Systemic Treatment of Oligometastatic Disease Efficacy of Immune Check-Point Inhibitors (ICPi) Ido Wolf, MD in Large Cell Neuroendocrine Tumors (LCNET) of Sourasky Medical Center, Tel-Aviv, Israel Lung Miscellaneous – Part I Shira Sherman, MD Moderators: Ronen Brenner, MD Davidoff Cancer Center, Rabin Medical Center, , , Israel Israel Hovav Nechushtan, MD Ablation of Cx3cr1-expressing Tumor-associated Hadassah Medical Center, Jerusalem, Israel Macrophages Significantly Increases Radiation 14.45-15.05 Integrative Oncology 2019 - Integrating Sensitivity in a Murine Lung Cancer Model Epigenetics, Tumor Microenvironment, and the Uri Amit, MD, MPH, PhD Patient as a Whole Sheba Medical Center, Ramat Gan, Israel Ofer Caspi, MD, PhD 12.30-13.15 Lunch (Continue in Tarshish Hall) Davidoff Center, Rabin Medical Center, Petach Keynote Lecture Tikva, Israel Moderator: Jamal Zidan, MD 15.05-15.25 Molecular Profiling in 2020: Wishes and Facts Ziv Medical Center, Safed, Israel Natasha B. Leighl, M.D Princess Margaret Hospital, Toronto, Canada Supported by Oncotest Rhenium 15.25-15.40 Coffee Break Friday, January 10, 2020 Miscellaneous – Part II Moderators: Gil Bar-Sela, MD 07.30-08.10 Meet the Professor - Breast Cancer HaEmek Medical Center, , Israel Tarshish A Hall Dror Limon, MD Sourasky Medical Center, Tel-Aviv, Israel Rinat Yerushalmi, MD Davidoff Center, Rabin Medical Center, Petach 15.40-16.00 Adjuvant Treatment of Melanoma Tikva, Israel Peter Mohr, MD Supported by Roche Elbe Kliniken, Stade, Germany Breast – Part I Supported by Novartis Moderators: Ella Evron, MD 16.00-16.20 Treatment of Metastatic Melanoma , , Israel Michal Lotem, MD Hadassah Medical Center, Jerusalem, Israel Eli Sapir, MD Supported by BMS Assuta Medical Center, Ashdod, Israel 16:20-16:40 Treatment of Advanced Non-Melanoma Skin 08.20-08.40 Escalation & De-Escalation Strategies - The Cancer Challenging Journey Towards Precision Gil Tauber, MD Medicine in Early Breast Cancer Rabin Medical Center, Petach Tikva, Israel Shani Paluch-Shimon, MD Supported by Sanofi Shaare Zedek Medical Center, Jerusalem, Israel Supported by Roche 16:40-17:00 Metastatic H&N Cancer Aron Popovtzer, MD 08.40-09.00 Modern RT in Breast Cancer Davidoff Center, Rabin Medical Center, Petach Yasmin Korzets, MD Tikva, Israel Davidoff Center, Rabin Medical Center, Petach Supported by MSD Tikva, Israel 09.00-09.20 Targeted Therapies in Metastatic Breast Cancer 17:00-17:20 Advances in the Treatment of Ovarian Cancer Amir Sonnenblick, MD, PhD Tamar Safra, MD Sourasky Medical Center, Tel-Aviv, Israel Sourasky Medical Center, Tel-Aviv, Israel Supported by Novartis Supported by AstraZeneca and MSD 09.20-09.50 Pro & Con: Low Dose Tamoxifen for Every Woman 17:20-17:40 Cannabis: Myth or Reality? with High Risk for Breast Cancer Ora Rosengarten, MD Shaare Zedek Medical Center, Jerusalem, Israel Moderator: Tamar Peretz, MD Hadassah Medical Center, Jerusalem, Israel Pro: Rinat Yerushalmi, MD Davidoff Center, Rabin Medical Center, Petach Tikva, Israel Con: Larissa Rivo, MD Assuta Medical Center, Ashdod, Israel 09.50-10.30 Tumor Board - Breast Cancer 11.15-11.30 Best of Breast 2019 Moderator: Noa Efrat Ben-Baruch, MD Nava Siegelmann-Danieli, MD Kaplan Medical Center, Rehovot, Israel Maccabi Health Services, Israel Panel: Einav Gal Yam, MD, PhD Supported by Lilly Sheba Medical Center, Ramat-Gan, Israel 11.30-12.20 Original Abstracts – Part IV: Irina Jeveliuk, MD Evolution in the Risk of Adverse Events of Assuta Medical Center, Tel-Aviv, Israel Adjuvant Endocrine Therapy in Postmenopausal Women with Early-Stage Breast Cancer Bella Kaufman, MD Daniel Reinhorn, MD Sheba Medical Center, Ramat-Gan, Israel Davidoff Center, Rabin Medical Center, Petach Yasmin Korzets, MD Tikva, Israel Davidoff Center, Rabin Medical Center, Petach Ethnicity, Recurrence Score (RS) Distribution, Tikva, Israel and Clinical Outcomes in ER+ HER2-Negative Tanir M. Allweis, MD Breast Cancer (BC) Patients Tested Through Kaplan Medical Center, Rehovot, Israel (CHS) in Israel Shani Paluch-Shimon, MD Gil Bar-Sela, MD Shaare Zedek Medical Center, Jerusalem, Israel HaEmek Medical Center, Afula, Israel Gilad W. Vainer MD, PhD De-Escalating Adjuvant Trastuzumab in HER2 Hadassah Medical Center, Jerusalem, Israel Positive Early-Stage Breast Cancer: A Systemic Supported by Roche Review and Meta-analysis 10.30-10.45 Coffee Break Hadar Goldvaser, MD Davidoff Center, Rabin Medical Center, Petach Breast Cancer – Part II Tikva, Israel Moderators: Ayelet Shay, MD , , Israel Deconstructing Klotho: From Experimental Model to Developing Novel Anti-Neoplastic Liana Abdach, MD Therapy Rambam Medical Center, Haifa, Israel Hagai Ligumsky, MD, PhD 10.45-11.15 Pro & Con: IORT in Early Breast Cancer Sourasky Medical Center, , Israel Moderator: Merav Ben David, MD Prognostic & Predictive Implications of Absolute Assuta Medical Center, Tel-Aviv, Israel Lymphocytes Count 7 Days After Adoptive Cell Pro: Yonina Tova, MD Therapy with Tumor Infiltrating Lymphocytes Assuta Medical Center, Tel-Aviv, Israel Guy Ben-Betzalel, MD Sheba Medical Center, Ramat Gan, Israel Con: Orit Kaidar-Person, MD Rambam Medical Center, Haifa, Israel Supported by Medison 12.20-12.45 Grant Awards Moderator: Gal Markel, MD, PhD Sheba Medical Center, Ramat Gan, Israel 12:45 Closing Remarks 13:00 Lunch 13:30-15:00 ISCORT Forum Meeting This program was printed with the support of Roche Pharmaceuticals (Israel) Ltd.